多股评 | Professional Stock Review | Investor Community

US IPO View: SpaceX AI revenue may exceed $320B by 2030

65 Browse
US IPO View: SpaceX AI revenue may exceed $320B by 2030
## Goldman Sachs: SpaceX AI Division Revenue to Reach $322B by 2030 According to the Financial Times, Goldman Sachs revealed to potential investors that SpaceX's AI division revenue is expected to soar from $3.2B in 2025 to $322B by 2030, a nearly 100x increase. - 2026: AI division operating revenue expected $15.6B (up 3.9% YoY) - 2027: AI division operating revenue expected $34.5B ## Total Revenue Also Up: $474B by 2030 Goldman also estimates SpaceX's total revenue will grow from $18.7B last year to $474B by 2030. ## Evercore ISI: AI Division Sales $755B by 2031 Evercore ISI analysts expect SpaceX AI sales to reach $755B by 2031; last year it was only $3.2B, a 234x increase. The AI revenue surge could support SpaceX's target valuation of up to $1.8 trillion. ## Cash Flow Path: Negative $105B in 2029, Positive Over $72B by 2031 Goldman's team also expects SpaceX's free cash flow to turn positive and exceed $72B by 2031 after hitting a trough of -$105B in 2029.
Disclaimer

The content of this article is for market analysis, investment knowledge popularization, and personal opinion sharing only, and does not constitute any investment advice. Stock market investment involves risks, please invest cautiously.

More Views

Explore more expert articles

Unveiling the
US Stock AI Computing Intelligence

Unveiling the "Fuel Room" of AI: A Comprehensive Analysis of the US Stock AI Computing Power Industry Chain and Investment Logic

Read More
Policy Becomes the Biggest Variable in AI Computing Power: Export Controls and Sovereign AI Reshape the Valuation Map of the U.S. Compute Industry Chain
US Stock AI Computing Intelligence

Policy Becomes the Biggest Variable in AI Computing Power: Export Controls and Sovereign AI Reshape the Valuation Map of the U.S. Compute Industry Chain

Read More
Is a Higher Dividend Yield Always Better? A Three-Step Beginner's Breakdown of US Dividend Pharma Stocks — How AI Is Rewriting High-Yield Valuation Logic
US Stock Dividend Medical Insight

Is a Higher Dividend Yield Always Better? A Three-Step Beginner's Breakdown of US Dividend Pharma Stocks — How AI Is Rewriting High-Yield Valuation Logic

Read More
Success
Operation completed successfully!